Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Retained Earnings (2021 - 2025)

Coeptis Therapeutics Holdings has reported Retained Earnings over the past 5 years, most recently at -$110.0 million for Q4 2025.

  • Quarterly results put Retained Earnings at -$110.0 million for Q4 2025, down 12.16% from a year ago — trailing twelve months through Dec 2025 was -$110.0 million (down 12.16% YoY), and the annual figure for FY2025 was -$110.0 million, down 12.16%.
  • Retained Earnings for Q4 2025 was -$110.0 million at Coeptis Therapeutics Holdings, down from -$108.4 million in the prior quarter.
  • Over the last five years, Retained Earnings for COEPW hit a ceiling of -$3.2 million in Q1 2021 and a floor of -$110.0 million in Q4 2025.
  • Median Retained Earnings over the past 5 years was -$80.4 million (2023), compared with a mean of -$62.3 million.
  • Biggest five-year swings in Retained Earnings: grew 18.82% in 2022 and later tumbled 1953.64% in 2023.
  • Coeptis Therapeutics Holdings' Retained Earnings stood at -$27.6 million in 2021, then plummeted by 139.89% to -$66.1 million in 2022, then crashed by 32.18% to -$87.4 million in 2023, then decreased by 12.23% to -$98.0 million in 2024, then dropped by 12.16% to -$110.0 million in 2025.
  • The last three reported values for Retained Earnings were -$110.0 million (Q4 2025), -$108.4 million (Q3 2025), and -$106.0 million (Q2 2025) per Business Quant data.